UNSPSC 51401710: Olanzapine pamoate

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7S6Q4MHCB. European Medicines Agency schedules Olanzapine embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32279. Olanzapine pamoate generally arises in the molecular formula C23H16O6.C17H20N4S.H2O. The term 'olanzapine pamoate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule olanzapine pamoate under HS 29349990.

As of Q4 2014, OLANZAPINE PAMOATE remains US FDA's Preferred Term for this commodity. Olanzapine pamoate bears US NLM identifiers UMLS ID C2698647 and NCI Concept Code C76442. SMILES: CC1CC2C(S1)NC3CCCCC3N=C2N4CCN(CC4)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.O.

UNSPSC 51401710 Olanzapine pamoate is a Commodity code, but the recent state and local procurement record shows minimal activity directly aligned with this specific antipsychotic pharmaceutical. The three most recent opportunities posted under this code are a naloxone and drug deactivation systems procurement by Seminole County, Florida; a Request for Information from the Texas Health and Human Services Commission exploring direct-to-manufacturer prescription programs; and a multistate generic pharmaceuticals and over-the-counter products RFP by the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). None of these solicitations target olanzapine pamoate specifically, and the misalignment between the code's nominal scope and actual procurement activity suggests either inconsistent code assignment in state procurement systems or that olanzapine pamoate solicitation activity does not currently surface at the state and local level with sufficient frequency to generate representative opportunities under this Commodity classification.

State and local purchasing activity visible under this code includes broad pharmaceutical contracting through cooperative purchasing vehicles such as MMCAP, which aggregates demand across multiple states and local government facilities, and direct health authority procurements such as Seminole County's community health initiatives and Texas HHS's exploratory market-intelligence work on direct-to-manufacturer models. The geographic spread reflects participation by Florida, Texas, Minnesota, and Oregon through cooperative structures. The MMCAP RFP, posted January 20, 2026 with a March 26, 2026 response deadline, represents the largest visible contracting vehicle, requiring manufacturers to provide comprehensive pricing and product compliance data through authorized wholesalers, while the Texas HHS RFI and Seminole County IFB suggest state health agencies are exploring alternative contracting models to reduce cost and improve fulfillment. Without recent solicitations specifically requesting olanzapine pamoate, the code appears inactive as a direct procurement driver at the state and local level; firms pursuing this market should monitor cooperative purchasing catalogs and state Medicaid pharmacy benefit notices rather than relying on activity patterns under this Commodity classification alone.